The project “Be The Cure” (BTCure) is one of eight projects which are funded by the Innovative Medicine Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The aim of the BTCure program is to develop new treatment methods for Rheumatoid Arthritis (RA).
BTCure will investigate molecular mechanisms, which initiate disease to prevent disease before the onset of joint destruction. The focus of our subprojects is the investigation of preclinical models to develop new therapy approaches. Hereby we concentrate on Wnt signalling, which is decisive for the determination of disease activity. With the use of serum samples taken at biobanks and multicentre progression data base we can validate the results of preclinical models. The new findings can be integrated into new therapeutic strategies for the treatment of RA.
Contact: Prof. Dr. med. Georg Schett